0000000001269701

AUTHOR

S. Bruno

showing 12 related works from this author

Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis.

2010

A genome-wide association screen for primary biliary cirrhosis risk alleles was performed in an Italian cohort. The results from the Italian cohort replicated IL12A and IL12RB associations, and a combined meta-analysis using a Canadian dataset identified newly associated loci at SPIB (P = 7.9 × 10−11, odds ratio (OR) = 1.46), IRF5-TNPO3 (P = 2.8 × 10−10, OR = 1.63) and 17q12-21 (P = 1.7 × 10−10, OR = 1.38).

Liver CirrhosisOncologyCanadamedicine.medical_specialtyCirrhosisEuropean Continental Ancestry GroupLOCIPRIMARY BILIARY CIRRHOSIS; GENOME WIDE ASSOCIATION; LOCIGenome-wide association studyLocus (genetics)genetics Genome Genome-Wide Association Study Humans Interferon Regulatory Factors Liver CirrhosiBiologyBiliary Meta-Analysis as Topic Odds RatioWhite PeopleArticleGENOME WIDE ASSOCIATIONAlleles Canada European Continental Ancestry Groupprimary biliary cirrhosiPrimary biliary cirrhosisMeta-Analysis as TopicMED/12 - GASTROENTEROLOGIAIL12AInternal medicineOdds RatioGeneticsmedicineHumansAllelegenomeAlleles Canada European Continental Ancestry Group; genetics Genome Genome-Wide Association Study Humans Interferon Regulatory Factors Liver Cirrhosis; Biliary Meta-Analysis as Topic Odds RatioAllelesprimary biliary cirrhosis genome-wide meta-analysesGeneticsLiver Cirrhosis BiliaryBiliaryOdds ratiomedicine.diseasePrimary biliary cirrhosisInterferon Regulatory FactorsCohortGenome-Wide Association Study
researchProduct

Reappraisal of prognostic value of MELD-Na score: A new tool for liver transplant prioritization in HCV-infected patients

2014

Prioritizationmedicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicineIntensive care medicinebusinessValue (mathematics)Digestive and Liver Disease
researchProduct

Safety and efficacy of peginterferon alpha 2a plus mycofenolatemofetile and peginterferon alpha 2a plus Ribavirin in unresponsive patients with chron…

2005

researchProduct

Evidence for the production of three massive vector bosons with the ATLAS detector

2019

A search for the production of three massive vector bosons in proton–proton collisions is performed using data at TeV recorded with the ATLAS detector at the Large Hadron Collider in the years 2015–2017, corresponding to an integrated luminosity of 79.8 fb−1. Events with two same-sign leptons ℓ (electrons or muons) and at least two reconstructed jets are selected to search for . Events with three leptons without any same-flavour opposite-sign lepton pairs are used to search for , while events with three leptons and at least one same-flavour opposite-sign lepton pair and one or more reconstructed jets are used to search for . Finally, events with four leptons are analysed to search for and .…

13000 GeV-cmsLarge hadron collider((n)jet dilepton) [final state]W: leptonic decay01 natural sciences7. Clean energySubatomär fysikvector boson: multiple productionElectroweak interactionscattering [p p]ATLAS LHC jets leptonsBoson((n)jet 3lepton) [final state]Collisionsmultiple production [W]Nuclear Experiment((n)jet 4lepton) [final state]Large Hadron ColliderPhysicsElectroweak interactionParticle physicslcsh:QC1-999:Mathematics and natural scienses: 400::Physics: 430::Nuclear and elementary particle physics: 431 [VDP]muon: pair production(3lepton) [final state]CERN LHC CollProduction (computer science)colliding beams [p p]p p: scatteringCiências Naturais::Ciências FísicasLHC ATLAS High Energy PhysicsHIGH ENERGY PHYSICSProduction (computer science)same signddc:530pair production [electron]010306 general physicsW: hadronic decayScience & Technology010308 nuclear & particles physicsfinal state: ((n)jet dilepton)Z0: associated productionExperimental High Energy PhysicsW bosonp p: colliding beamslcsh:PhysicsPhysics::Instrumentation and DetectorsAtlas detectormeasured [channel cross section]High Energy Physics - Experiment//purl.org/becyt/ford/1 [https]electron: pair productionW: pair productionHigh Energy Physics - Experiment (hep-ex)final state: ((n)jet 3lepton)Subatomic Physics[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]associated production [Z0]BosonPhysicsproton–proton collisionsSettore FIS/01 - Fisica SperimentaleATLASfinal state: (3lepton)pair production [W]LHCchannel cross section: measuredParticle Physics - ExperimentjetsNuclear and High Energy PhysicsParticle physics530 PhysicsAtlas detector:Ciências Físicas [Ciências Naturais]FOS: Physical sciencesmultiple production [vector boson]Computer Science::Digital Librariesvector boson: massive0103 physical sciencespair production [muon]hadronic decay [W]hep-exHigh Energy Physics::Phenomenology:Matematikk og naturvitenskap: 400::Fysikk: 430::Kjerne- og elementærpartikkelfysikk: 431 [VDP]Físicafinal state: (4lepton)(4lepton) [final state]//purl.org/becyt/ford/1.3 [https]leptonic decay [Z0]final state: ((n)jet 4lepton)W: multiple productionleptonic decay [W]Z0: leptonic decayPhysics::Accelerator PhysicsSpace scienceHigh Energy Physics::Experimentmassive [vector boson]Hadron-hadron collisionsexperimental results
researchProduct

Measurement of the production cross section for a Higgs boson in association with a vector boson in the H → WW⁎ → ℓνℓν channel in pp collisions at s=…

2019

A measurement of the Higgs boson production cross sections via associated WH and ZH production using H -> WW* -> l nu l nu decays, where l stands for either an electron or a muon, is presente ...

PhysicsNuclear and High Energy PhysicsParticle physicsLarge Hadron ColliderMuonPhysics::Instrumentation and Detectors010308 nuclear & particles physicsAtlas detectorHigh Energy Physics::PhenomenologyElectron01 natural sciencesVector boson0103 physical sciencesHiggs bosonHigh Energy Physics::Experiment010306 general physicsPhysics Letters B
researchProduct

Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S01688278173…

2018

It has come to our attention that the PITER framework investigator, Alessandro Federico, was incorrectly listed as F. Alessandro in the original manuscript. Please note that the correct name of this author is Alessandro Federico (2nd University of Naples). The correct list of PITER investigators is in the footnote below.

HepatologyHepatitis B; EASL guidelines; Treatment; Interferon; Entecavir; Tenofovir; TAF; HBsAg; Hepatocellular carcinoma; HBV DNA; HBV reactivation; Mother to child transmissionHepatocellular carcinomaHBV reactivationEASL guidelinesHepatitis BEntecavirTreatmentHBsAgTAFHBV DNAMother to child transmissionInterferonTenofovirEASL guideline
researchProduct

Current practice of chronic hepatitis B treatment in Southern Italy

2012

Abstract Background Treatment choice for chronic HBV infection is a continuously evolving issue, with a wide range of options. We aimed to evaluate the current practice of HBV therapies in the real world in Southern Italy. Methods A prospective study enrolling over a six month period (February–July 2010) all consecutive HBsAg positive subjects, never previously treated, referred to 16 liver units in two Southern Italy regions (Calabria and Sicily). Results Out of 247 subjects evaluated, 116 (46.9%) had HBV-DNA undetectable or lower than 2000 UI/ml. There were 108 (43.7%) inactive carriers, 103 (41.7%) chronic hepatitis, and 36 (14.6%) liver cirrhosis. Antiviral treatment was planned in 94 (…

AdultMalemedicine.medical_specialtyHBsAgGuanineCirrhosisOrganophosphonatesPyrimidinonesNucleosides analoguesAntiviral AgentsPolyethylene GlycolsYoung AdultHepatitis B ChronicChronic hepatitisInterferonPegylated interferonInternal medicineHBVInternal MedicinemedicineHumansHepatitis B e AntigensPractice Patterns Physicians'TenofovirProspective cohort studyAgedAged 80 and overTelbivudinebusiness.industryAdenineAge FactorsInterferon-alphaNucleosidesMiddle AgedHBV; Interferon; Nucleosides analogues; Nucleotides analoguesNucleotides analoguesmedicine.diseaseRecombinant ProteinsItalyLamivudineCurrent practiceImmunologyInterferonFemalePreviously treatedbusinessThymidinemedicine.drugEuropean Journal of Internal Medicine
researchProduct

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interfer…

2016

none 48 no Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infec…

Liver CirrhosisMaleCirrhosisDatabases FactualGastroenterologyHCV-infected cirrhotic patients; hepatocellular carcinoma; HCC; sustained viral eradication; SVR; interferon0302 clinical medicineRetrospective StudiePharmacology (medical)Prospective StudiesHCV-infected cirrhotic patientsHCCProspective cohort studyAged 80 and overLiver NeoplasmsGastroenterologyvirus diseasesHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCatheter AblationInterferon030211 gastroenterology & hepatologyFemaleLiver cancerHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularSVRLiver CirrhosiAntiviral AgentsFollow-Up Studie03 medical and health sciencesInternal medicinemedicineCarcinomaEarly Hepatocellular CarcinomaHumansAgedRetrospective StudiesAntiviral AgentHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNARetrospective cohort studymedicine.diseasedigestive system diseasesSurgeryProspective Studiesustained viral eradicationInterferonsNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3)…

2022

It has come to our attention that the name of one of the authors in our manuscript was incorrectly spelled ‘Jinyoung Byan’; the correct spelling is ‘Jinyoung Byun’ as in the author list above. In addition, the excel files of the supplementary tables were not included during the online publication of our article. These have now been made available online. We apologize for any inconvenience caused.

PBC
researchProduct

Measurement of photon?jet transverse momentum correlations in 5.02 TeV Pb + Pb and pp collisions with ATLAS

2019

Jets created in association with a photon can be used as a calibrated probe to study energy loss in the medium created in nuclear collisions. Measurements of the transverse momentum balance between isolated photons and inclusive jets are presented using integrated luminosities of 0.49 nb−1 of Pb + Pb collision data at TeV and 25 pb−1 of pp collision data at TeV recorded with the ATLAS detector at the LHC. Photons with transverse momentum GeV and are paired with all jets in the event that have GeV and pseudorapidity . The transverse momentum balance given by the jet-to-photon ratio, , is measured for pairs with azimuthal opening angle . Distributions of the per-photon jet yield as a function…

PhotonLEAD-LEAD COLLISIONS; PP COLLISIONS; ROOT-S(NN)=2.76 TEV; DEPENDENCEheavy ion: scatteringPhysics::Instrumentation and DetectorsMonte Carlo methodRelativistic heavy ion collisionsphoton–jet transverse momentum correlationsnucl-ex01 natural sciencesHigh Energy Physics - ExperimentDouble Drell–YanSubatomär fysikHigh Energy Physics - Experiment (hep-ex)Double parton-scatteringDEPENDENCESubatomic Physicsscattering [p p][PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]luminositiesCollisions ROOT-S(NN)=2.76 TEVNuclear Experiment (nucl-ex)Nuclear Experimentdimension: 2GeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)Nuclear ExperimentMonte CarloComputingMilieux_MISCELLANEOUSQCComputer Science::DatabasesPhysicsJet (fluid)Large Hadron ColliderSettore FIS/01 - Fisica Sperimentalephotonyield [jet]transverse momentum: correlationATLASlcsh:QC1-999:Mathematics and natural scienses: 400::Physics: 430::Nuclear and elementary particle physics: 431 [VDP]medicine.anatomical_structureCERN LHC Coll2 [dimension]nuclear matterLHCLEAD-LEAD COLLISIONSjet: yieldParticle Physics - ExperimentNuclear and High Energy Physicsp p: scatteringenergy loss [parton]530 PhysicsCiências Naturais::Ciências FísicasAstrophysics::High Energy Astrophysical Phenomena:Ciências Físicas [Ciências Naturais]FOS: Physical sciencesddc:500.2LHC ATLAS High Energy Physics[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]jets Nuclear physicsAtlas (anatomy)0103 physical sciencesCalibrationmedicineddc:530RapidityNuclear Physics - Experiment5020 GeV-cms/nucleonHigh Energy Physics010306 general physicsCiencias ExactasFour-lepton productionHiggs golden decay channelPP COLLISIONSScience & Technology010308 nuclear & particles physicshep-exHigh Energy Physics::Phenomenologynucleus:Matematikk og naturvitenskap: 400::Fysikk: 430::Kjerne- og elementærpartikkelfysikk: 431 [VDP]FísicaNuclear mattercalibrationjet quenching* Automatic Keywords *rapidityExperimental High Energy PhysicsHigh Energy Physics::Experimentparton: energy losscorrelation [transverse momentum]lcsh:Physicsexperimental resultsPhysics Letters B
researchProduct

EFFICACY AND SAFETY OF BOCEPREVIR-BASED THERAPY IN HCVG1 TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS: THE ITALIAN AND SPANISH NPP…

2014

Background and Aims: To maximize cost/efficay of boceprevirbased triple therapy (BOC) in patients with HCV-related advanced fibrosis/cirrhosis. Methods: ITT SVR12, safety and futility rules value were evaluated in the multicenter national Italian and Spanish early access Name- Patient-Program which includes treatment-experienced patients with HCVG1-related advanced fibrosis/cirrhosis (Metavir F3/4) treated with BOC in both countries. Results: 402 patients (mean age 55 years; range 22–75), 316 (78.6%) G1b, 255 (63.4%) F4, 60 (30.9%) with oesophageal varices, 137 (34.1%) relapsers, 95 (23.6%) partial and 168 (41.8%) null responders were enrolled. Platelets count <100,000 and albumin levels <3…

CHRONIC HCVSettore MED/12 - GastroenterologiaSettore MED/09 - Medicina InternaHEPATITIS CCIRRHOSISHEPATITIS C; CIRRHOSIS; CHRONIC HCV
researchProduct

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

2017

Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N= 200) and w…

Male0301 basic medicinehepatitis C virusSustained Virologic ResponseSofosbuvirHepacivirusDrug ResistanceHepacivirusresistance-associated substitutionsViral Nonstructural ProteinsVARIANTSNS5Amedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrenceINFECTIONantiviral therapyMedicinehepatitis C viruViralTreatment FailureChronicantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; hepatologybiologyGENOTYPE 1virus diseasesMiddle Agedantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutionsSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCombinationInterferonDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAuthor Keywords:antiviral therapyRIBAVIRINSequence AnalysisHumanmedicine.drugmedicine.medical_specialtyDaclatasvirGenotypeHepatitis C virusAntiviral AgentsLONG-TERM PERSISTENCEDACLATASVIR03 medical and health sciencesDrug Therapyantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; Aged; Antiviral Agents; Drug Resistance Viral; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; HepatologyTREATMENT-NAIVEInternal medicineDrug Resistance ViralRibavirinHumansNS5Aresistance testdirect-acting antiviralsAgedAntiviral Agentresistance-associated substitutiondirect-acting antiviralHepaciviruHepatologyresistance test KeyWords Plus:HEPATITIS-C VIRUSbusiness.industryRibavirinViral Nonstructural ProteinSequence Analysis DNADNAHepatitis C ChronicHepatologybiology.organism_classificationClinical trial030104 developmental biologySOFOSBUVIRchemistrySequence AnalysihepatologyMutationImmunologyInterferonsSofosbuvirbusiness
researchProduct